Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model
Miriam Redondo(Instituto de Química Médica), Carmen Gil(Instituto de Salud Carlos III), Marı́a A. Moro(Instituto de Salud Carlos III), Marı́a Isabel Cadavid(Universidade de Santiago de Compostela), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Juan G. Zarruk(Universidad Complutense de Madrid), Plácido A. Ceballos(Instituto de Química Médica), Daniel I. Pérez(Cedars-Sinai Medical Center), José Brea(Universidade de Santiago de Compostela), Marı́a Isabel Loza(Universidade de Santiago de Compostela), Cristina Val(Universidade de Santiago de Compostela), Concepción Pérez(Instituto de Química Médica), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas)
Cited by 72
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
|PLoS Pathogens|2016|451
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334